中文摘要：

目的观察补肾活血化痰法对肾虚精亏、痰瘀内阻型颈动脉粥样硬化失眠患者睡眠质量的影响。方法前瞻性连续收集2010年8月至2012年8月于首都医科大学宣武医院中医科就诊的失眠患者138例,排除不符合纳入标准者32例、未能按规定服药者5例、自行退出者4例,最终纳入颈动脉粥样硬化斑块伴失眠患者97例进行研究,按数字表法,将其随机分为观察组（49例）与对照组（48例）。观察组给予补肾活血化痰中药治疗,对照组给予地西泮治疗,疗程均为4周。采用匹兹堡睡眠质量指数量表（PSQI）评价患者的睡眠质量,不良反应量表（TESS）评价药物干预后出现的不良反应。结果 （1）治疗后观察组患者睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠紊乱、安眠药物、日间功能及总分分别为（0.97±0.31）、（1.09±0.44）、（1.2±0.6）、（0.8±0.3）、（1.5±0.5）、（0.0±0.0）、（0.39±0.15）、（3.2±0.9）分,治疗前分别为（2.25±0.31）、（2.17±0.67）、（1.7±0.5）、（1.7±0.4）、（1.6±0.3）、（1.8±0.5）、（1.77±0.72）、（10.0±1.2）分,治疗前后睡眠质量、入睡时间、睡眠效率、安眠药物、日间功能及总分的差异均有统计学意义（均P〈0.01）,其余指标治疗前后差异均无统计学意义（均P〉0.05）。（2）治疗后对照组患者睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠紊乱、安眠药物、日间功能及总分分别为（1.51±0.21）、（1.11±0.33）、（1.4±0.6）、（1.4±0.5）、（1.5±0.5）、（1.1±0.4）、（1.98±0.59）、（8.0±1.3）分,治疗前分别为（1.98±0.51）、（2.20±0.27）、（1.5±0.6）、（1.4±0.6）、（1.6±0.7）、（1.1±0.4）、（2.11±0.61）、（10.8±2.3）分,治疗前后睡眠质量、入睡时间及总分的差异均有统计学意义（均P〈0.05）,其余指标治疗前后差异均无统计学意义（均P〉0.05）。治疗后,观察?

英文摘要：

Abstract： Objective To observe the effects of tonifyting kidney, promoting blood circulation and resolving phlegm on the sleep quality of kidney vacuity and essence depletion or intermingled phlegm and blood stasis type carotid atherosclerosis patients with insomnia. Methods A total of 138 consecutive patients with insomnia visited the Department of Traditional Chinese Medicine, Xuanwu Hospital, Capital Medical University from August 2010 to August 2012 were collected prospectively. Thirty-two patients who did not meet the inclusion criteria and 5 who failed to take the prescribed medication were excluded, and 4 patients withdrew from the treatment. Finally ,97 carotid atheroselernsis patients with insomnia were enrolled in the study. According to the random number table method, the patients were completely randomized into either an observation group （n = 49） or a control group （ n = 48）. The observation group was treated with tonifyting kidney, promoting blood circulation and resolving phlegm, the control group was treated with diazepam, and the course of treatment was 4 weeks for both groups. The sleeping quality of the patients was assessed by the Pittsburgh sleep quality index （PSQI）. The adverse reactions after pharmacological inter- vention were assessed by the treatment emergent symptoms scale （TESS）. Results （ 1 ） The sleep quality, time of failing asleep, hours of sleep, sleep efficiency, sleep disorders, sleeping pills, daytime function, and total score after treatment in patients of the observation group were （0.97±0.31）、（1.09±0.44）、（1.2±0.6）、（0.8±0.3）、（1.5±0.5）、（0.0±0.0）、（0.39±0.15） and （3.2±0.9）, respectively, those before treatment were （2.25±0.31）、（2.17±0.67）、（1.7±0.5）、（1.7±0.4）、（1.6±0.3）、（1.8±0.5）、（1.77±0.72） adnd （10.0±1.2） respectively. There were significant differences in sleep quality, time of falling asleep, sleeping efficiency, sleeping pill, daytime function and tot